Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258856 · ClinicalTrials.gov registry record · Phase 2
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
A Phase 2 study of Meningitis and Meningococcal Infection, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
- 11
- Study locations
NCT00258856 is a Phase 2 study of Meningitis and Meningococcal Infection that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 234 participants, below the 654-participant average among 7 other Meningitis trials with a reported enrollment target (64% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT00258856, a Phase 2 study of Meningitis and Meningococcal Infection, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
- 11
- Study locations
Study Summary
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years (not yet 16 years) who had been vaccinated five years previously in Study 603-02. In addition, the kinetics of the antibody response will be evaluated in a subset of participants who will receive a booster dose of Menactra® vaccine and children in the same age group not previously vaccinated with a meningococcal vaccine or had meningitis disease who will receive a dose of Menactra® vaccine.
Conditions Studied
Interventions
- BIOLOGICAL Polysaccharide Diphtheria Conjugate Vaccine
Study Locations (11)
Arkansas
- - Jonesboro
- - Little Rock
Pennsylvania
- - Pittsburgh
- - Sellersville
Georgia
- - Marietta
Maryland
- - Baltimore
Massachusetts
- - Woburn
Missouri
- - Bridgeton
New York
- - Rochester
Utah
- - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258856
The ClinicalTrials.gov registry entry for NCT00258856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 654-participant average among 7 other Meningitis trials with a reported enrollment target (64% lower). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Meningitis appearing as the primary indexed condition, and to 1 intervention - of which Polysaccharide Diphtheria Conjugate Vaccine is the first listed.
NCT00258856 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Arkansas, Pennsylvania, Georgia.
Frequently Asked Questions
What is clinical trial NCT00258856 about?
NCT00258856 is a clinical study titled "Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®". The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years (not yet 16 years) who had been vaccinated five years previously in Study 603-02. In addition, the kinetics of the antibody response will be evaluated in a subset of participants who will rece...
What is the current status of trial NCT00258856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2006-01. Estimated completion is 2007-11.
What conditions does trial NCT00258856 study?
This clinical trial studies the following conditions: Meningitis, Meningococcal Infection.
What interventions are being tested in trial NCT00258856?
The interventions under investigation include: Polysaccharide Diphtheria Conjugate Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00258856?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00258856 being conducted?
This trial has 11 study locations across Arkansas, Georgia, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
COMPLETED · Phase 2
-
Hypovitaminosis D in Neurocritical Patients
COMPLETED · Phase 2
-
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
COMPLETED · Phase 2
-
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
COMPLETED · Phase 3
-
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
COMPLETED · Phase 3
-
Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.